Inovio Noncontrolling Interest In Consolidated Entity from 2010 to 2024
| INO Stock | USD 4.35 0.03 0.69% |
Noncontrolling Interest In Consolidated Entity | First Reported 2011-06-30 | Previous Quarter 96.3 K | Current Value 96.3 K | Quarterly Volatility 885.9 K |
Check Inovio Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Inovio Pharmaceuticals' main balance sheet or income statement drivers, such as Depreciation And Amortization of 2.4 M, Interest Expense of 1.2 M or Total Revenue of 790.4 K, as well as many indicators such as Price To Sales Ratio of 155, Dividend Yield of 1.0E-4 or PTB Ratio of 1.1. Inovio financial statements analysis is a perfect complement when working with Inovio Pharmaceuticals Valuation or Volatility modules.
Inovio | Noncontrolling Interest In Consolidated Entity |
Latest Inovio Pharmaceuticals' Noncontrolling Interest In Consolidated Entity Growth Pattern
Below is the plot of the Noncontrolling Interest In Consolidated Entity of Inovio Pharmaceuticals over the last few years. It is Inovio Pharmaceuticals' Noncontrolling Interest In Consolidated Entity historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Inovio Pharmaceuticals' overall financial position and show how it may be relating to other accounts over time.
| Noncontrolling Interest In Consolidated Entity | 10 Years Trend |
|
Noncontrolling Interest In Consolidated Entity |
| Timeline |
Inovio Noncontrolling Interest In Consolidated Entity Regression Statistics
| Arithmetic Mean | 1,011,074 | |
| Geometric Mean | 0.00 | |
| Coefficient Of Variation | 92.14 | |
| Mean Deviation | 860,840 | |
| Median | 546,768 | |
| Standard Deviation | 931,570 | |
| Sample Variance | 867.8B | |
| Range | 2.4M | |
| R-Value | 0.78 | |
| Mean Square Error | 366.5B | |
| R-Squared | 0.61 | |
| Significance | 0.0006 | |
| Slope | 162,404 | |
| Total Sum of Squares | 12.1T |
Inovio Noncontrolling Interest In Consolidated Entity History
About Inovio Pharmaceuticals Financial Statements
Inovio Pharmaceuticals investors utilize fundamental indicators, such as Noncontrolling Interest In Consolidated Entity, to predict how Inovio Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
| Last Reported | Projected for Next Year | ||
| Noncontrolling Interest In Consolidated Entity | 2.3 M | 2.4 M |
Pair Trading with Inovio Pharmaceuticals
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Inovio Pharmaceuticals position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Inovio Pharmaceuticals will appreciate offsetting losses from the drop in the long position's value.Moving together with Inovio Stock
Moving against Inovio Stock
| 0.78 | VCYT | Veracyte | PairCorr |
| 0.72 | VERA | Vera Therapeutics | PairCorr |
| 0.66 | SABSW | SAB Biotherapeutics | PairCorr |
| 0.57 | DRUG | Bright Minds Biosciences Trending | PairCorr |
| 0.51 | VCEL | Vericel Corp Ord | PairCorr |
The ability to find closely correlated positions to Inovio Pharmaceuticals could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Inovio Pharmaceuticals when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Inovio Pharmaceuticals - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Inovio Pharmaceuticals to buy it.
The correlation of Inovio Pharmaceuticals is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Inovio Pharmaceuticals moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Inovio Pharmaceuticals moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Inovio Pharmaceuticals can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out the analysis of Inovio Pharmaceuticals Correlation against competitors. To learn how to invest in Inovio Stock, please use our How to Invest in Inovio Pharmaceuticals guide.You can also try the Watchlist Optimization module to optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Inovio Pharmaceuticals. If investors know Inovio will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Inovio Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (4.43) | Revenue Per Share 0.025 | Quarterly Revenue Growth (0.55) | Return On Assets (0.40) | Return On Equity (0.91) |
The market value of Inovio Pharmaceuticals is measured differently than its book value, which is the value of Inovio that is recorded on the company's balance sheet. Investors also form their own opinion of Inovio Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Inovio Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Inovio Pharmaceuticals' market value can be influenced by many factors that don't directly affect Inovio Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Inovio Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Inovio Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Inovio Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.